Statins / lipid screening (primary prevention) ⭐

statins-primary-prevention · high-yield

← back to Preventive & Ambulatory Medicine

Summary

The 2026 ACC/AHA dyslipidemia guideline replaces the 2018 cholesterol guideline and broadens scope to include hypertriglyceridemia and elevated Lp(a). Major changes include adoption of the PREVENT-ASCVD risk equations (replacing the Pooled Cohort Equations) with lower treatment thresholds, reinstatement of explicit LDL-C and non–HDL-C goals, universal once-in-a-lifetime Lp(a) measurement, expanded role for apoB testing, and incorporation of newer agents (bempedoic acid, inclisiran, evinacumab, olezarsen) alongside statins, ezetimibe, and PCSK9 mAbs. The guideline emphasizes the “CPR” framework (Calculate–Personalize–Reclassify with CAC) and earlier intervention to reduce lifetime atherogenic lipoprotein exposure.

Current guideline: 2026 ACC/AHA Dyslipidemia Guideline · download Anki sub-deck

Versions